New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
07:36 EDTMDT, BCRMedtronic balloon likely to be superior to C.R. Bard product, says Wells Fargo
After examining data disclosed by C.R. Bard (BCR) on its drug-coated balloon, Wells Fargo thinks the efficacy of Medtronic's drug-coated balloon will be superior. The firm keeps an Outperform rating on Medtronic.
News For MDT;BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
15:35 EDTMDTMedtronic announces consent decree with FDA for Synchromed system
Subscribe for More Information
15:31 EDTMDTFDA enters consent decree with Medtronic
The FDA announced the filing of a consent decree against Medtronic and two of the company’s officers—S. Omar Ishrak and Thomas Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump Systems, medical devices that deliver medication to treat primary or metastatic cancer, chronic pain and severe spasticity. These violations occurred at the company’s Neuromodulation facilities in Columbia Heights, Minnesota, where the devices are manufactured. The legal action requires the company to stop manufacturing, designing and distributing new Synchromed II Implantable Infusion Pump Systems except in very limited cases, such as when a physician determines that the Synchromed II Implantable Infusion Pump System is medically necessary for a patient’s treatment. The consent decree also requires Medtronic to retain a third-party expert to help develop and submit plans to the FDA to correct violations. The consent decree will remain in effect until the FDA has determined that Medtronic has met all the provisions listed in the consent decree.
11:02 EDTMDTMedtronic begins clinical study of Endurant Evo AAA strent graft system
Subscribe for More Information
April 24, 2015
09:37 EDTBCRC.R. Bard upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
April 23, 2015
17:40 EDTBCRC.R. Bard sees Q2 EPS $2.15-$2.19, consensus $2.18
Subscribe for More Information
17:29 EDTBCRC.R. Bard sees FY15 EPS $8.95-$9.05, consensus $9.00
Guidance provided on Q1 earnings conference call.
16:18 EDTBCRC.R. Bard reports Q1 adjusted EPS $2.10, consensus $2.07
Reports Q1 revenue $819.7M, consensus $813.88M.
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 17, 2015
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use